Willow

Provider Profile Name: Willow
Website: startwillow.com
Type: Direct-to-consumer telehealth — Virtual Only
Chief Medical Officer: Dr. Michael Green, MD, OB/GYN (dual board-certified, 30+ years experience)
Primary Audience: Women, though open to all adults 18+
Available In: Currently 33 states, with plans to expand nationwide

Operating Details

• Fully virtual — no in-person visits required
• No insurance required; HSA/FSA accepted
• Same-day doctor approval available; free discreet shipping
• Patients 18+ eligible; diabetes is an exclusion; pre-diabetes and hypertension are accepted
• No doctor’s referral required

Approach Willow is dedicated to improving women’s overall well-being by making personalized weight loss medication accessible to every body, partnering with board-certified doctors and leading pharmacies to make this possible at a price affordable to most women, not just celebrities. The company operates alongside Winona, a well-established women’s HRT telehealth platform, and shares the same chief medical officer, giving it a stronger clinical infrastructure than many solo-launched GLP-1 platforms.

About the Company

Willow is Winona’s sister company. The two brands are related, sharing Dr. Michael Green as CMO across both platforms. Winona is an established HRT company for women in perimenopause and menopause. This lineage is notable: Willow inherits backend clinical infrastructure, pharmacy partnerships, and operational experience from a company that has been building women’s telehealth for longer than the GLP-1 boom.

Dr. Michael Green is a dual board-certified physician with over 30 years of experience and Willow’s Chief Medical Officer. He is also a GLP-1 patient himself, having successfully lost weight on both compounded semaglutide and tirzepatide, which gives Willow first-hand insight into the patient experience.

One meaningful differentiator and point of controversy in Willow’s model is its approach to eligibility. Willow markets its medications for everyone, even those who are not overweight and only have a few pounds to lose, in contrast to most compounded GLP-1 providers that set BMI thresholds. The platform’s FAQ confirms adults 18+ who are not pregnant or breastfeeding, and who do not have certain medical conditions that make treatment unsafe, are eligible, though diabetes is an exclusion. Prospective patients should verify their state’s eligibility and discuss appropriate candidacy with their assigned physician.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

GLP-1 Offerings and Weight Loss Services

Willow offers three compounded GLP-1 medication formats. No FDA-approved brand-name medications are available through the platform.

Medications Available:

• Compounded Semaglutide (Injectable) — administered once weekly as a subcutaneous injection; may include Cyanocobalamin (Vitamin B12) as a complementary ingredient
• Compounded Semaglutide (Oral/Sublingual) — taken daily by placing a tablet under the tongue, where it dissolves and is absorbed directly into the bloodstream; needle-free alternative
• Compounded Tirzepatide (Injectable) — weekly injection targeting both GLP-1 and GIP receptors; the more powerful and more expensive option

Compounded semaglutide formulations at Willow may include Cyanocobalamin (Vitamin B12) to support energy levels, personalized to align with the patient’s goals and physiology.

An important caveat on the oral sublingual semaglutide: this format has attracted significant criticism in the broader compounded GLP-1 market. Unlike FDA-approved oral semaglutide (Wegovy tablets), which uses a specialized absorption-enhancing technology (SNAC), most compounded sublingual versions do not include this component, raising questions about actual bioavailability and clinical effectiveness. Some Willow patients have reported no appetite suppression or weight loss on the oral format, and this is consistent with broader scientific skepticism about the efficacy of compounded sublingual semaglutide delivery. The injectable formats do not carry this concern.

The program includes a personalized GLP-1 medication plan, same-day approval, free shipping, unlimited physician access, and 24/7 Care Team support. Patients who prefer a different pharmacy may send their prescription there, with a platform fee applying.

Pricing by Type — and What Reviewers Say

Willow’s pricing is straightforward and all-inclusive:

• Compounded Semaglutide (Injectable): $299/month for most dosages includes prescription, medication, and free 2-day shipping
• Plans range from $299 to $549/month, depending on the specific medication and dosage prescribed
• No insurance required; HSA/FSA accepted
• No consultation fee

Many Willow patients lose up to 20% of their body weight, with visible results in just a few months, according to the company’s published claims. These figures reflect the clinical trial data for semaglutide and tirzepatide as classes, not Willow-specific compounded product outcomes.

What reviewers say about pricing over time: Reviewers who report good results with the injectable formats describe the pricing as fair and all-inclusive. The main friction point is the oral sublingual semaglutide format; multiple reviewers describe spending $300/month for 2–3 months without any weight loss or appetite change, then being advised to switch to injections. One reviewer spent $600 over two months on oral semaglutide tablets with no weight loss, no side effects, and no clinical effect. Another spent $900 over three months with zero results. Patients who are considering the oral format should discuss efficacy expectations with their Willow physician before selecting that pathway.

Reviews from Trustpilot and Google

Willow has 315 reviews on Trustpilot. The feedback follows a bimodal distribution, strongly positive from injectable users who see results, and strongly negative from those who either experienced ineffective oral formulations, medication quality concerns, or customer service failures.

What patients praise:

• Significant weight loss on injectable formats reviewers cite losses of 26 lbs in three months, 34 lbs in seven months, and 27 lbs with minimal lifestyle changes
• Responsive physicians, with some reviewers describing same-day doctor replies even on evenings and weekends
• Clear communication throughout the enrollment, payment, pharmacy processing, and delivery stages
• Easy process for FSA receipts and medical necessity letters

Common complaints:

• Oral semaglutide is consistently described as ineffective by a subset of reviewers, “nothing but a mint candy,” “placebo,” and “wasted $900” appear across multiple independent reviews
• Medication quality complaints for some batches of injectable semaglutide, with users reporting increased appetite or weight gain after switching to Willow from another provider, raising questions about potency consistency between compounding runs
• Customer service delays reported by some users email is the primary contact method, and responses can take multiple days during high-volume periods; no phone support
• Shipping delays: one reviewer reported a second order arriving with no medication inside; another described waiting over a month from sign-up to receiving a first order

Compounding Pharmacies Used

Willow does not publicly identify its partner compounding pharmacies and does not specify whether they operate as 503A or 503B facilities. The company refers to them as “trusted U.S. pharmacy partners” with “strict quality standards and ongoing oversight,” but independent verification is not possible without knowing the specific pharmacy names.

Patients can opt to send their Willow prescription to a pharmacy of their own choosing, with a platform fee applying, provided the pharmacy can fill the compound exactly as written. This opt-out option is notable, as it gives patients the ability to use a pharmacy they’ve researched independently, which addresses the transparency gap to some degree.

Patients wanting to vet the compounding source should ask Willow directly which pharmacy will fill their prescription, then verify that pharmacy’s state licensing, PCAB or NABP accreditation status, and whether batch-level Certificates of Analysis are available.

Note: Willow prescribes compounded GLP-1 medications only; no FDA-approved brand-name medications are available through this platform. The oral sublingual semaglutide format has attracted a meaningful volume of negative reviews citing no clinical effect; patients interested in this format should discuss bioavailability expectations with their assigned physician before selecting it. Compounding pharmacy partners are not publicly named. State availability is currently limited to 33 states. Confirm your state before enrolling. Willow’s low-BMI prescribing approach is a differentiator but also a point of clinical controversy; appropriateness should be discussed with the prescribing physician. All pricing reflects the company’s published rates as of early 2026 and is subject to change.